吉非替尼治疗Ⅳ期非小细胞肺癌的效果及对肿瘤标志物水平的影响  

Effect of Gefitinib on Tumor Markers of StageⅣNon-small Cell Lung Cancer Chemotherapy

作　　者：潘鑫焱[1] 李志民[1] PAN Xin-yan;LI Zhi-min(Dalian City Central Hospital,Liaoning Province 116033)

机构地区：[1]辽宁省大连市中心医院肿瘤一科,辽宁大连116033

出　　处：《医学临床研究》2019年第2期274-276,共3页Journal of Clinical Research

摘　　要：【目的】探讨吉非替尼在Ⅳ期非小细胞肺癌(NSCLC)患者化疗中的疗效。【方法】在本院治疗的Ⅳ期NSCLC患者72例,根据不同治疗方案分为观察组(n=34)和对照组(n=38),对照组给予顺鋪联合培美曲赛治疗,观察组给予顺粕联合吉非替尼治疗,比较两组疗效及对肿瘤标志物的影响。【结果】观察组总有效率为91.18%(31/34),明显优于对照组的81.58%(31/38),且差异有显著性(P<0.05)0观察组骨髓抑制、腹泻的发生率明显高于对照组(P<0.05)。观察组治疗后癌胚抗原(CEA)、细胞角蛋白片段21-1(CYFRA21-1)及鳞状细胞癌抗原(SCCA)明显低于对照组(P<0.05);观察组中位无进展生存时间和总体生存期分别为9个月和13个月,明显高于对照组5个月和9个月(P<0.05)。【结论】Ⅳ期NSCLC患者采用吉非替尼化疗有较好的临床疗效,可显著降低CEA、CYFRA21-1及SCCA水平,值得临床使用。【Objective】To investigate the effect of gefitinib in the treatment of stage IV non-small cell lung cancer(NSCLC).【Methods】A total of 72 patients with stageⅣNSCLC in our hospital were divided into the observation group(n=34)and the control group(n=38).Patients in the control group were treated with cisplatin plus pimitrex,while patients in the observation group were given cisplatin plus gefitinib.The therapeutic effects and tumor marker changes in the two groups were compared.【Results】The short-term curative effect of the observation group was significantly better than that of the control group(P<0.05),which of clinical effective rates were 91.18%and 81.58%,respectively,The rates of bone marrow suppression and diarrhea in the observation group were significantly higher than those in the control group(P V0.05),After treatment,the paracancerous antigen(CEA),cytokeratin fragment 21-1(CYFRA21-1)and squamous cell carcinoma antigen(SCCA)in the observation group were(30.03±11.02)g/L,(25.58±6.22)g/L and(25.50±5.44)g/L,respectively,which were significantly lower than those of the control group(P V0.05).The median progression-free survival time and overall survival in the observation group were 9 months and 13 months,respectively,which were significantly longer than those in the control group(5 months and 9 months,respectively)(P<0.05).【Conclusion】Gefitinib has good clinical efficacy in the treatment of stage IV non-small cell lung cancer patients which can significantly reduce CEA,CYFRA21-1 and SCCA levels.It is worthy of clinical use.

关 键 词：癌 非小细胞肺/药物疗法 抗肿瘤药/治疗应用 

分 类 号：R730.26[医药卫生—肿瘤]